Samuel Guan Wei Ow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samuel Guan Wei Ow has a total of 293 co-authors. Here are the top co-authors by number of shared publications:
- David Shao Peng Tan
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
42 shared publications - Natalie Yan Li Ngoi
Department of Haematology-Oncology, National University Cancer Institute, Singapore
38 shared publications - Bee Choo Tai
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore
25 shared publications - Kidong Kim
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
25 shared publications - Siew Eng Lim
Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
25 shared publications - Tuan Zea Tan
Genomics and Data Analytics Core, Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore
25 shared publications
Latest Publications
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3  (4)
Single-Arm Combined Phase I/II Study Evaluating Limb Cryocompression to Prevent Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxane-Based Chemotherapy
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity of taxane-based chemotherapy with no established preventive strategy. We evaluated the safety, tolerability, and efficacy of a novel limb cryocompression device in reducing CIPN. Methods: In this prospective single-arm phase I/II study conducted at three sites in Singapore, patients with cancer scheduled for taxane-based chemotherapy received limb cryocompression (11°C; cyclic compression 5-15 mm Hg), starting 30 minutes before, during, and 30 minutes after taxane infusion. Primary end points included safety, tolerability, and clinically significant CIPN. CIPN was assessed by physician-graded Common Terminology Criteria for Adverse Events (CTCAE) and the patient-reported European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN 20-item scale (EORTC QLQ-CIPN20). A ≥3-point increase in the EORTC QLQ-CIPN20 sensory subscale defined clinically significant patient-reported CIPN. Taxane dose modifications attributable to CIPN were recorded. Results: A total of 150 patients were enrolled (median age 52 years; 96.6% female; 89.0% breast cancer). Taxane regimens included paclitaxel (71.2%), docetaxel (28.1%), and nab-paclitaxel (0.68%); 44.5% received concurrent scalp cooling. A total of 146 patients were evaluable as four patients withdrew before commencing cryocompression. Tolerability was 84.2%; 123 patients completed all cryocompression cycles without premature termination. Fifteen patients (10.3%) withdrew because of cold intolerance. At treatment completion, 22.8% had CTCAE G1 CIPN and 1.6% had G2 CIPN; none developed G3/4 CIPN. Clinically significant patient-reported sensory CIPN occurred in 13.9% at 12 weeks and 13.1% at 24 weeks, and 5.7% required taxane dose modification because of CIPN. Conclusion: Limb cryocompression is safe, well-tolerated, and associated with low rates of clinically significant CIPN in patients receiving taxane-based chemotherapy. A multicenter randomized controlled trial is ongoing to validate these findings (SWOG S2205 ICE COMPRESS; ClinicalTrials.gov identifier: NCT05642611 ).
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3  (4)
Single-Arm Combined Phase I/II Study Evaluating Limb Cryocompression to Prevent Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxane-Based Chemotherapy
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity of taxane-based chemotherapy with no established preventive strategy. We evaluated the safety, tolerability, and efficacy of a novel limb cryocompression device in reducing CIPN. Methods: In this prospective single-arm phase I/II study conducted at three sites in Singapore, patients with cancer scheduled for taxane-based chemotherapy received limb cryocompression (11°C; cyclic compression 5-15 mm Hg), starting 30 minutes before, during, and 30 minutes after taxane infusion. Primary end points included safety, tolerability, and clinically significant CIPN. CIPN was assessed by physician-graded Common Terminology Criteria for Adverse Events (CTCAE) and the patient-reported European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN 20-item scale (EORTC QLQ-CIPN20). A ≥3-point increase in the EORTC QLQ-CIPN20 sensory subscale defined clinically significant patient-reported CIPN. Taxane dose modifications attributable to CIPN were recorded. Results: A total of 150 patients were enrolled (median age 52 years; 96.6% female; 89.0% breast cancer). Taxane regimens included paclitaxel (71.2%), docetaxel (28.1%), and nab-paclitaxel (0.68%); 44.5% received concurrent scalp cooling. A total of 146 patients were evaluable as four patients withdrew before commencing cryocompression. Tolerability was 84.2%; 123 patients completed all cryocompression cycles without premature termination. Fifteen patients (10.3%) withdrew because of cold intolerance. At treatment completion, 22.8% had CTCAE G1 CIPN and 1.6% had G2 CIPN; none developed G3/4 CIPN. Clinically significant patient-reported sensory CIPN occurred in 13.9% at 12 weeks and 13.1% at 24 weeks, and 5.7% required taxane dose modification because of CIPN. Conclusion: Limb cryocompression is safe, well-tolerated, and associated with low rates of clinically significant CIPN in patients receiving taxane-based chemotherapy. A multicenter randomized controlled trial is ongoing to validate these findings (SWOG S2205 ICE COMPRESS; ClinicalTrials.gov identifier: NCT05642611 ).
- Open Access
- 9 April 2026
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 55  (6) , 339
Decentralised germline genetic testing for epithelial ovarian cancer in a tertiary Asian centre
- 9 April 2026
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 55  (6) , 339
Open AccessDecentralised germline genetic testing for epithelial ovarian cancer in a tertiary Asian centre
- Open Access
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9  (9) , e2400243
Augmenting Large Language Models With National Comprehensive Cancer Network Guidelines for Improved and Standardized Adjuvant Therapy Recommendations in Postoperative Breast Cancer Cases
PURPOSE: Multidisciplinary breast tumor boards (MTBs) are essential for optimizing breast cancer treatment but face challenges related to logistics, variability in expertise, and lack of standardization. Large language models may support clinical decision making. This study evaluates the accuracy of adjuvant therapy recommendations generated by an artificial intelligence (AI)–driven tool, TheSerenityBot (TSB), in comparison with Claude-2 and GPT-4, using expert MTB consensus as the reference. METHODS: Postoperative breast cancer cases reviewed at the National University Hospital, Singapore, between June and November 2023 were retrospectively analyzed. Eligible patients were women with invasive or preinvasive breast cancer who underwent surgery. Metastatic cases were excluded. TSB, a Claude-2–based model augmented with 2023 National Comprehensive Cancer Network guidelines, generated adjuvant therapy recommendations across seven treatment modalities. Outputs from TSB, Claude-2, and GPT-4 were evaluated for concordance with MTB recommendations. Model performance was assessed using generalized estimating equations. RESULTS: Fifty patients were included (mean age, 59.8 years); 75.5% had hormone receptor–positive tumors, and 60.0% underwent breast-conserving surgery. TSB demonstrated the highest overall accuracy (0.89), followed by Claude-2 (0.86) and GPT-4 (0.78). GPT-4 showed significantly lower accuracy in genetic testing recommendations (odds ratio [OR], 0.05 [95% CI, 0.015 to 0.149]; P < .001), whereas Claude-2 was less accurate in radiotherapy recommendations (OR, 0.41 [95% CI, 0.17 to 0.98]; P = .040). CONCLUSION: A guideline-augmented AI tool such as TSB shows promise in supporting adjuvant therapy decisions in breast cancer. To improve clinical relevance, future iterations will incorporate individualized patient factors, broader guideline frameworks, and electronic health record integration. Prospective trials are ongoing to assess the real-world impact.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9  (9) , e2400243
Open AccessAugmenting Large Language Models With National Comprehensive Cancer Network Guidelines for Improved and Standardized Adjuvant Therapy Recommendations in Postoperative Breast Cancer Cases
PURPOSE: Multidisciplinary breast tumor boards (MTBs) are essential for optimizing breast cancer treatment but face challenges related to logistics, variability in expertise, and lack of standardization. Large language models may support clinical decision making. This study evaluates the accuracy of adjuvant therapy recommendations generated by an artificial intelligence (AI)–driven tool, TheSerenityBot (TSB), in comparison with Claude-2 and GPT-4, using expert MTB consensus as the reference. METHODS: Postoperative breast cancer cases reviewed at the National University Hospital, Singapore, between June and November 2023 were retrospectively analyzed. Eligible patients were women with invasive or preinvasive breast cancer who underwent surgery. Metastatic cases were excluded. TSB, a Claude-2–based model augmented with 2023 National Comprehensive Cancer Network guidelines, generated adjuvant therapy recommendations across seven treatment modalities. Outputs from TSB, Claude-2, and GPT-4 were evaluated for concordance with MTB recommendations. Model performance was assessed using generalized estimating equations. RESULTS: Fifty patients were included (mean age, 59.8 years); 75.5% had hormone receptor–positive tumors, and 60.0% underwent breast-conserving surgery. TSB demonstrated the highest overall accuracy (0.89), followed by Claude-2 (0.86) and GPT-4 (0.78). GPT-4 showed significantly lower accuracy in genetic testing recommendations (odds ratio [OR], 0.05 [95% CI, 0.015 to 0.149]; P < .001), whereas Claude-2 was less accurate in radiotherapy recommendations (OR, 0.41 [95% CI, 0.17 to 0.98]; P = .040). CONCLUSION: A guideline-augmented AI tool such as TSB shows promise in supporting adjuvant therapy decisions in breast cancer. To improve clinical relevance, future iterations will incorporate individualized patient factors, broader guideline frameworks, and electronic health record integration. Prospective trials are ongoing to assess the real-world impact.
- Open Access
- 23 October 2025
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 4
Multimodality Imaging to Detect Anthracycline-induced Cardiotoxicity in Breast Cancer Patients: A Mechanistic Pilot Study (The MIDAC Study)
Background: Anthracycline-induced cardiotoxicity remains highly prevalent among cancer patients undergoing chemotherapy and its pathophysiology remains poorly understood. Objective: In the Multimodality Imaging to Detect Anthracycline-induced Cardiotoxicity (MIDAC) study, the aim was to use hybrid cardiac PET/MRI to provide mechanistic insights into the pathophysiology of anthracycline-induced cardiotoxicity. Methods: Seventeen female breast cancer patients scheduled for doxorubicin chemotherapy were prospectively recruited to undergo serial cardiac imaging at baseline (PET/MRI), 3 months (PET/MRI) and 12 months post-chemotherapy (MRI only). Results: Compared to baseline, at 3 months there was: a reduction in left ventricular ejection fraction (57 ± 6% versus 62 ± 4%; p<0.001); a reduction in both global circumferential and longitudinal strain (global circumferential strain and global longitudinal strain); higher native myocardial T1 values (1,304 ± 35 versus 1,260 ± 51 ms; p=0.004); increased extracellular volume fraction (29 ± 3% versus 26 ± 3%; p=0.012); a reduction in intracellular mass (44 ± 7 versus 47 ± 8 g; p=0.03); and a reduction in standardised uptake values of fluorine-18 fluorodeoxyglucose uptake (4.2 ± 2.3 versus 6.2 ± 2.6; p=0.012). There was a positive correlation between relative standardised uptake values reductions and global longitudinal strain at 3 months (R 0.54, p=0.032). At 12 months, left ventricular ejection fraction remained lower than baseline (56 ± 6% versus 62 ± 4%; p<0.001) with an associated reduction in global circumferential strain and global longitudinal strain. Native myocardial T1 values remained higher than baseline but with no significant differences in T2, intracellular mass and extracellular volume fraction. Conclusion: Observations at 3 months post-doxorubicin chemotherapy were diffuse interstitial fibrosis, a reduction in intracellular mass, and a reduction in myocardial glucose metabolism; changes which were associated with a reduction in global longitudinal strain and left ventricular ejection fraction. Diffuse interstitial fibrosis persisted at 12 months and was associated with lower left ventricular ejection fraction and global longitudinal strain.
- 23 October 2025
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 4
Open AccessMultimodality Imaging to Detect Anthracycline-induced Cardiotoxicity in Breast Cancer Patients: A Mechanistic Pilot Study (The MIDAC Study)
Background: Anthracycline-induced cardiotoxicity remains highly prevalent among cancer patients undergoing chemotherapy and its pathophysiology remains poorly understood. Objective: In the Multimodality Imaging to Detect Anthracycline-induced Cardiotoxicity (MIDAC) study, the aim was to use hybrid cardiac PET/MRI to provide mechanistic insights into the pathophysiology of anthracycline-induced cardiotoxicity. Methods: Seventeen female breast cancer patients scheduled for doxorubicin chemotherapy were prospectively recruited to undergo serial cardiac imaging at baseline (PET/MRI), 3 months (PET/MRI) and 12 months post-chemotherapy (MRI only). Results: Compared to baseline, at 3 months there was: a reduction in left ventricular ejection fraction (57 ± 6% versus 62 ± 4%; p<0.001); a reduction in both global circumferential and longitudinal strain (global circumferential strain and global longitudinal strain); higher native myocardial T1 values (1,304 ± 35 versus 1,260 ± 51 ms; p=0.004); increased extracellular volume fraction (29 ± 3% versus 26 ± 3%; p=0.012); a reduction in intracellular mass (44 ± 7 versus 47 ± 8 g; p=0.03); and a reduction in standardised uptake values of fluorine-18 fluorodeoxyglucose uptake (4.2 ± 2.3 versus 6.2 ± 2.6; p=0.012). There was a positive correlation between relative standardised uptake values reductions and global longitudinal strain at 3 months (R 0.54, p=0.032). At 12 months, left ventricular ejection fraction remained lower than baseline (56 ± 6% versus 62 ± 4%; p<0.001) with an associated reduction in global circumferential strain and global longitudinal strain. Native myocardial T1 values remained higher than baseline but with no significant differences in T2, intracellular mass and extracellular volume fraction. Conclusion: Observations at 3 months post-doxorubicin chemotherapy were diffuse interstitial fibrosis, a reduction in intracellular mass, and a reduction in myocardial glucose metabolism; changes which were associated with a reduction in global longitudinal strain and left ventricular ejection fraction. Diffuse interstitial fibrosis persisted at 12 months and was associated with lower left ventricular ejection fraction and global longitudinal strain.
- 17 October 2025
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 79, 103017
Experiences, support needs, and coping strategies of women with early-stage breast cancer in Singapore: A qualitative study
- 17 October 2025
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 79, 103017
Experiences, support needs, and coping strategies of women with early-stage breast cancer in Singapore: A qualitative study
- Open Access
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Purpose:The optimal treatment of recurrent ovarian clear cell carcinoma (rOCCC) remains unknown. This is the first randomized trial to compare durvalumab with chemotherapy in rOCCC.Patients and Methods:MOCCA is a randomized, phase 2 trial conducted in Singapore, Korea, and Australia. Eligible patients had rOCCC with recurrence after platinum-based chemotherapy, Eastern Cooperative Oncology Group performance status ≤2, and no prior immune checkpoint blockade. Patients were randomly assigned (2:1) to durvalumab (1,500 mg every 4 weeks) or chemotherapy. Patients progressing on chemotherapy were allowed to cross over to durvalumab. The primary outcome was progression-free survival. Secondary outcomes included overall survival, objective response rates, and safety.Results:Forty-eight eligible women were assigned to durvalumab (N = 31) or chemotherapy (N = 17). The median progression-free survival was 7.6 [95% confidence interval (CI), 7.0–16.0] and 14.0 (95% CI, 7.0–32.9) weeks with durvalumab and chemotherapy, respectively (HR = 1.6; 95% CI, 0.8–3.0; P = 0.92). The median overall survival was 37.9 (95% CI, 21.7–143.0) and 40.6 (95% CI, 25.0–not reached) weeks, respectively (HR = 1.5; 95% CI, 0.7–3.3; P = 0.85). The difference in objective response rates between the groups was not statistically significant (durvalumab 9.7% vs. physician’s choice chemotherapy 18.8%; difference −9.1%; 95% CI, −31.3% to 12.9%; P = 0.83). Fewer all-grade (35.5% vs. 68.8%) and high-grade (9.7% vs. 31.3%) treatment-related adverse events were observed for durvalumab. PD-L1 combined positive score (CPS)+ was observed in 28.9% (CPS ≥1%) and 10.5% (CPS ≥10%) of patients. PIK3CA mutations were associated with time to progression on durvalumab ≥12 weeks [relative risk (mutated vs. wild-type) 2.83; 95% CI, 1.16–14.17].Conclusions:Durvalumab was well-tolerated but did not improve efficacy outcomes compared with chemotherapy in rOCCC.
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Purpose:The optimal treatment of recurrent ovarian clear cell carcinoma (rOCCC) remains unknown. This is the first randomized trial to compare durvalumab with chemotherapy in rOCCC.Patients and Methods:MOCCA is a randomized, phase 2 trial conducted in Singapore, Korea, and Australia. Eligible patients had rOCCC with recurrence after platinum-based chemotherapy, Eastern Cooperative Oncology Group performance status ≤2, and no prior immune checkpoint blockade. Patients were randomly assigned (2:1) to durvalumab (1,500 mg every 4 weeks) or chemotherapy. Patients progressing on chemotherapy were allowed to cross over to durvalumab. The primary outcome was progression-free survival. Secondary outcomes included overall survival, objective response rates, and safety.Results:Forty-eight eligible women were assigned to durvalumab (N = 31) or chemotherapy (N = 17). The median progression-free survival was 7.6 [95% confidence interval (CI), 7.0–16.0] and 14.0 (95% CI, 7.0–32.9) weeks with durvalumab and chemotherapy, respectively (HR = 1.6; 95% CI, 0.8–3.0; P = 0.92). The median overall survival was 37.9 (95% CI, 21.7–143.0) and 40.6 (95% CI, 25.0–not reached) weeks, respectively (HR = 1.5; 95% CI, 0.7–3.3; P = 0.85). The difference in objective response rates between the groups was not statistically significant (durvalumab 9.7% vs. physician’s choice chemotherapy 18.8%; difference −9.1%; 95% CI, −31.3% to 12.9%; P = 0.83). Fewer all-grade (35.5% vs. 68.8%) and high-grade (9.7% vs. 31.3%) treatment-related adverse events were observed for durvalumab. PD-L1 combined positive score (CPS)+ was observed in 28.9% (CPS ≥1%) and 10.5% (CPS ≥10%) of patients. PIK3CA mutations were associated with time to progression on durvalumab ≥12 weeks [relative risk (mutated vs. wild-type) 2.83; 95% CI, 1.16–14.17].Conclusions:Durvalumab was well-tolerated but did not improve efficacy outcomes compared with chemotherapy in rOCCC.
- Open Access
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Chemotherapy regimens received by patients randomized to physician’s choice chemotherapy
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Chemotherapy regimens received by patients randomized to physician’s choice chemotherapy
- Open Access
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Supplementary Figure S5 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Supplementary Figure S5 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
- Open Access
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Longitudinal analyses of EORTC QLQ-C30 and QLQ-OV28 scores, comparing physician’s choice chemotherapy (red) and durvalumab (blue); PCC: physician’s choice chemotherapy; D: durvalumab; QoL: quality of life; GI: gastrointestinal
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Longitudinal analyses of EORTC QLQ-C30 and QLQ-OV28 scores, comparing physician’s choice chemotherapy (red) and durvalumab (blue); PCC: physician’s choice chemotherapy; D: durvalumab; QoL: quality of life; GI: gastrointestinal
- Open Access
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Supplementary Figure S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
- 16 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
Supplementary Figure S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial